Andrew P. Combs

Biography

Andrew P. Combs, Ph.D., Vice President, Discovery Chemistry, Incyte Corporation Andrew P. Combs, Ph.D., joined Incyte in 2003 where he is currently a Vice President of Discovery Chemistry. Prior to Incyte, Dr. Combs was a Director at Bristol-Myers Squibb and Dupont-Merck. He has led several medicinal chemistry programs in oncology to novel candidates, three of which are currently in human clinical trials. The most advanced is epacadostat, a first-in-class IDO1 inhibitor, which is expected to enter pivotal phase 3 trials in combination with pembrolizumab, an anti-PD1, for advanced melanoma in 2016. His passion for research embraces the application of innovative technologies to expedite the invention of new chemical entities. He has co-authored >100 research articles/posters/book chapters, an inventor on >30 patents, co-chaired >10 conferences and served on editorial advisory boards of several scientific journals (currently J. Med. Chem. Letters). Dr. Combs was a HHMI postdoctoral fellow in the laboratories of Prof. Schreiber at Harvard from 1994-1996 and holds a Ph.D. in Organic Chemistry from UCLA and BS degrees in Chemistry and Molecular Biology from the UW-Madison.

Research Interest

 microbiology